Imaging the N-methyl-D-aspartate receptors (NMDARs) in the living human brain by positron emission tomography (PET) or single photon emission computed tomography (SPECT) would provide useful information on the role of these receptors in ischemia and in various neurological disorders such as degenerative diseases, epilepsy or schizophrenia. To assess NMDAR radiotracer development and to propose perspectives, we overviewed the PET and SPECT candidate radioligands developed until now. Labelled molecules of interest were classified in three groups according to their binding site: intrachannel pore site blockers, glycine site inhibitors and NR2B selective subunit antagonists.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/138955710791608299 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Noninvasive in vivo imaging of macrophages: understanding tumor microenvironments and delivery of therapeutics.
Biomark Res
January 2025
BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Sciences, School of Medicine, Kyungpook National University, Daegu, 41944, Korea.
Macrophages are pivotal in the body's defense and response to inflammation. They are present in significant numbers and are widely implicated in various diseases, including cancer. While molecular and histological techniques have advanced our understanding of macrophage biology, their precise function within the cancerous microenvironments remains underexplored.
View Article and Find Full Text PDFA multiplexing method based on multidimensional readout method.
Phys Med Biol
January 2025
Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Guangqiao Load, Shenzhen, 518132, CHINA.
To develop and validate a novel multidimensional readout method that significantly reduces the number of readout channels in PET detectors while maintaining high spatial and energy performance. Approach: We arranged a 3×3×4 SiPM array in multiple dimensions and employed row/column/layer summation with a resistor-based splitting circuit. We then applied denoising methods to enhance the peak-to-valley ratio in the decoding map, ensuring accurate crystal-position determination.
View Article and Find Full Text PDFLu-Labeled Heterodimeric Agent with High Stability Targeting Neovascularization for Tumor Radioligand Therapy.
J Med Chem
January 2025
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Radiopharmaceutical theranostics holds significant promise in tumor diagnosis and treatment, but suboptimal tumor uptake and retention remain a persistent limitation. We have conjugated a unique albumin binder to our previously developed heterodimeric precursor HX01 and achieved a novel precursor L6, aiming to prolong circulation time and enhance tumor accumulation and retention. However, we observed that the NGR sequence of L6 was gradually rearranged to iso-DGR under alkaline conditions, resulting in decreased stability.
View Article and Find Full Text PDFPET, SPECT, and MRI imaging for evaluation of Parkinson's disease.
Am J Nucl Med Mol Imaging
December 2024
Department of Radiology, University of Pennsylvania Philadelphia, PA 19104, USA.
This review assesses the primary neuroimaging techniques used to evaluate Parkinson's disease (PD) - a neurological condition characterized by gradual dopamine-producing nerve cell degeneration. The neuroimaging techniques explored include positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). These modalities offer varying degrees of insights into PD pathophysiology, diagnostic accuracy, specificity by way of exclusion of other Parkinsonian syndromes, and monitoring of disease progression.
View Article and Find Full Text PDFInitial clinical experience with [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.
Front Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!